Correlation of the Geriatric Assessment with Overall Survival in Older Patients with Cancer

Abstract

AimsGlobal guidelines recommend that all older patients with cancer receiving chemotherapy should undergo a geriatric assessment. However, utilisation of the geriatric assessment is often constrained by its time-intensive nature, which limits its adoption in settings with limited resources and high demand. There is a lack of evidence correlating the results of the geriatric assessment with survival from the Indian subcontinent. Therefore, the aims of the present study were to assess the impact of the geriatric assessment on survival in older Indian patients with cancer and to identify the factors associated with survival in these older patients. Materials and methodsThis was an observational study, conducted in the geriatric oncology clinic of the Tata Memorial Hospital (Mumbai, India). Patients aged 60 years and older with cancer who underwent a geriatric assessment were enrolled. We assessed the non-oncological geriatric domains of function and falls, nutrition, comorbidities, cognition, psychology, social support and medications. Patients exhibiting impairment in two or more domains were classified as frail. ResultsBetween June 2018 and January 2022, we enrolled 897 patients. The median age was 69 (interquartile range 65–73) years. The common malignancies were lung (40.5%), oesophagus (31.9%) and genitourinary (12.1%); 54.6% had metastatic disease. Based on the results of the geriatric assessment, 767 (85.4%) patients were frail. The estimated median overall survival in fit patients was 24.3 (95% confidence interval 18.2–not reached) months, compared with 11.2 (10.1–12.8) months in frail patients (hazard ratio 0.54; 95% confidence interval 0.41–0.72, P < 0.001). This difference in overall survival remained significant after adjusting for age, sex, primary tumour and metastatic status (hazard ratio 0.56; 95% confidence interval 0.41–0.74, P < 0.001). In the patients with a performance status of 0 or 1 (n = 454), 365 (80.4%) were frail; the median overall survival in the performance status 0–1 group was 33.0 months (95% confidence interval 24.31–not reached) in the fit group versus 14.4 months (95% confidence interval 12.25–18.73) in the frail patients (hazard ratio 0.50; 95% confidence interval 0.34–0.74, P = 0.001). In the multivariate analysis, the geriatric assessment domains that were predictive of survival were function (hazard ratio 0.68; 95% confidence interval 0.52–0.88; P = 0.003), nutrition (hazard ratio 0.64; 95% confidence interval 0.48–0.85, P = 0.002) and cognition (hazard ratio 0.67; 95% confidence interval 0.49–0.91, P = 0.011). DiscussionThe geriatric assessment is a powerful prognostic tool for survival among older Indian patients with cancer. The geriatric assessment is prognostic even in the cohort of patients thought to be the fittest, i.e. performance status 0 and 1. Our study re-emphasises the critical importance of the geriatric assessment in all older patients planned for cancer-directed therapy.